nodes	percent_of_prediction	percent_of_DWPC	metapath
Suramin—PLA2G4A—Fluocinolone Acetonide—psoriasis	0.798	1	CbGbCtD
Suramin—PLA2G2A—synovial fluid—psoriasis	0.0347	0.384	CbGeAlD
Suramin—F2—vertebral column—psoriasis	0.0135	0.149	CbGeAlD
Suramin—SIRT1—endothelium—psoriasis	0.0113	0.125	CbGeAlD
Suramin—F2—endothelium—psoriasis	0.006	0.0663	CbGeAlD
Suramin—ARSA—skin of body—psoriasis	0.00478	0.0529	CbGeAlD
Suramin—SIRT5—tendon—psoriasis	0.00445	0.0492	CbGeAlD
Suramin—P2RX4—tendon—psoriasis	0.00421	0.0465	CbGeAlD
Suramin—SIRT1—tendon—psoriasis	0.00369	0.0408	CbGeAlD
Suramin—RYR1—tendon—psoriasis	0.00341	0.0377	CbGeAlD
Suramin—PLA2G2A—tendon—psoriasis	0.00258	0.0285	CbGeAlD
Suramin—PLA2G4A—tendon—psoriasis	0.0018	0.0198	CbGeAlD
Suramin—PLA2G4A—Raltitrexed—Methotrexate—psoriasis	0.00177	0.291	CbGdCrCtD
Suramin—F2—Hemostasis—SERPINB8—psoriasis	0.000605	0.00573	CbGpPWpGaD
Suramin—PLA2G2A—Spinal Cord Injury—IL4—psoriasis	0.000569	0.00539	CbGpPWpGaD
Suramin—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriasis	0.000558	0.0053	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—SERPINB8—psoriasis	0.000553	0.00524	CbGpPWpGaD
Suramin—SIRT1—Signaling events mediated by HDAC Class I—STAT3—psoriasis	0.000543	0.00515	CbGpPWpGaD
Suramin—F2—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000538	0.0051	CbGpPWpGaD
Suramin—F2—IL1 and megakaryotyces in obesity—NFKB1—psoriasis	0.000527	0.005	CbGpPWpGaD
Suramin—PLA2G2A—Cardiac Hypertrophic Response—NFKB1—psoriasis	0.000527	0.005	CbGpPWpGaD
Suramin—SIRT1—Androgen receptor signaling pathway—JUN—psoriasis	0.000518	0.00492	CbGpPWpGaD
Suramin—PLA2G4A—PDGF Pathway—NFKBIA—psoriasis	0.000512	0.00486	CbGpPWpGaD
Suramin—F2—Folate Metabolism—CAT—psoriasis	0.000508	0.00481	CbGpPWpGaD
Suramin—SIRT1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	0.000505	0.00479	CbGpPWpGaD
Suramin—F2—Vitamin B12 Metabolism—CRP—psoriasis	0.000495	0.0047	CbGpPWpGaD
Suramin—F2—Vitamin B12 Metabolism—APOE—psoriasis	0.000485	0.0046	CbGpPWpGaD
Suramin—PLA2G2A—Spinal Cord Injury—LEP—psoriasis	0.000481	0.00456	CbGpPWpGaD
Suramin—ARSA—Metabolism—NDUFA5—psoriasis	0.000476	0.00451	CbGpPWpGaD
Suramin—ARSA—Metabolism of proteins—REN—psoriasis	0.000473	0.00448	CbGpPWpGaD
Suramin—SIRT1—Signaling events mediated by HDAC Class I—TNF—psoriasis	0.00047	0.00446	CbGpPWpGaD
Suramin—F2—Folate Metabolism—IL4—psoriasis	0.000466	0.00442	CbGpPWpGaD
Suramin—F2—Vitamin B12 Metabolism—ICAM1—psoriasis	0.000455	0.00432	CbGpPWpGaD
Suramin—RYR1—Transmembrane transport of small molecules—CP—psoriasis	0.000454	0.0043	CbGpPWpGaD
Suramin—SIRT1—Cellular responses to stress—CAT—psoriasis	0.000452	0.00429	CbGpPWpGaD
Suramin—PLA2G2A—Spinal Cord Injury—ICAM1—psoriasis	0.000452	0.00428	CbGpPWpGaD
Suramin—SIRT1—Androgen receptor signaling pathway—STAT3—psoriasis	0.000448	0.00425	CbGpPWpGaD
Suramin—PLA2G2A—Spinal Cord Injury—NOS2—psoriasis	0.000448	0.00425	CbGpPWpGaD
Suramin—ARSA—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000444	0.00421	CbGpPWpGaD
Suramin—SIRT1—Circadian rythm related genes—LEP—psoriasis	0.000437	0.00415	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—HCAR2—psoriasis	0.000435	0.00412	CbGpPWpGaD
Suramin—RYR1—Transmembrane transport of small molecules—CARM1—psoriasis	0.000433	0.00411	CbGpPWpGaD
Suramin—SIRT1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	0.000424	0.00402	CbGpPWpGaD
Suramin—P2RY2—GPCR downstream signaling—CCL20—psoriasis	0.000421	0.00399	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—HCAR2—psoriasis	0.00042	0.00398	CbGpPWpGaD
Suramin—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000419	0.00398	CbGpPWpGaD
Suramin—F2—Peptide ligand-binding receptors—CCL20—psoriasis	0.000417	0.00395	CbGpPWpGaD
Suramin—PLA2G4A—Betamethasone—Clobetasol propionate—psoriasis	0.000416	0.0686	CbGdCrCtD
Suramin—PLA2G4A—Dexamethasone—Clobetasol propionate—psoriasis	0.000416	0.0686	CbGdCrCtD
Suramin—PLA2G2A—Cardiac Hypertrophic Response—TNF—psoriasis	0.00041	0.00389	CbGpPWpGaD
Suramin—F2—GPCR ligand binding—HCAR2—psoriasis	0.00041	0.00388	CbGpPWpGaD
Suramin—P2RY2—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	0.00041	0.00388	CbGpPWpGaD
Suramin—SIRT1—Circadian rythm related genes—NOS2—psoriasis	0.000407	0.00386	CbGpPWpGaD
Suramin—FSHR—GPCR downstream signaling—CCL20—psoriasis	0.000406	0.00385	CbGpPWpGaD
Suramin—ARSA—Metabolism—CYP2S1—psoriasis	0.000405	0.00384	CbGpPWpGaD
Suramin—F2—Selenium Micronutrient Network—CAT—psoriasis	0.000403	0.00382	CbGpPWpGaD
Suramin—F2—Folate Metabolism—CRP—psoriasis	0.000403	0.00382	CbGpPWpGaD
Suramin—P2RY2—Signaling by GPCR—CCL20—psoriasis	0.000382	0.00362	CbGpPWpGaD
Suramin—SIRT1—Circadian rythm related genes—PPARG—psoriasis	0.000381	0.00361	CbGpPWpGaD
Suramin—RYR1—Myometrial Relaxation and Contraction Pathways—JUN—psoriasis	0.00038	0.00361	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—TAGAP—psoriasis	0.000377	0.00357	CbGpPWpGaD
Suramin—PLA2G2A—MicroRNAs in cardiomyocyte hypertrophy—NFKB1—psoriasis	0.000375	0.00356	CbGpPWpGaD
Suramin—F2—Folate Metabolism—ICAM1—psoriasis	0.00037	0.00351	CbGpPWpGaD
Suramin—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—JUN—psoriasis	0.00037	0.00351	CbGpPWpGaD
Suramin—FSHR—Signaling by GPCR—CCL20—psoriasis	0.000369	0.0035	CbGpPWpGaD
Suramin—RYR1—Myometrial Relaxation and Contraction Pathways—NFKB1—psoriasis	0.000366	0.00347	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—TAGAP—psoriasis	0.000364	0.00345	CbGpPWpGaD
Suramin—F2—Vitamin B12 Metabolism—IFNG—psoriasis	0.000346	0.00329	CbGpPWpGaD
Suramin—PLA2G2A—Spinal Cord Injury—IFNG—psoriasis	0.000344	0.00326	CbGpPWpGaD
Suramin—SIRT1—Integrated Breast Cancer Pathway—JUN—psoriasis	0.00034	0.00322	CbGpPWpGaD
Suramin—PLA2G4A—PDGF Pathway—JUN—psoriasis	0.000339	0.00322	CbGpPWpGaD
Suramin—PLA2G2A—MicroRNAs in cardiomyocyte hypertrophy—STAT3—psoriasis	0.000337	0.0032	CbGpPWpGaD
Suramin—PLA2G4A—AGE/RAGE pathway—NOS2—psoriasis	0.000336	0.00319	CbGpPWpGaD
Suramin—PLA2G4A—AGE/RAGE pathway—NFKBIA—psoriasis	0.000336	0.00319	CbGpPWpGaD
Suramin—PLA2G4A—Dexamethasone—Fluocinonide—psoriasis	0.000333	0.055	CbGdCrCtD
Suramin—PLA2G4A—Dexamethasone—Beclomethasone—psoriasis	0.000333	0.055	CbGdCrCtD
Suramin—PLA2G4A—Betamethasone—Fluocinonide—psoriasis	0.000333	0.055	CbGdCrCtD
Suramin—PLA2G4A—Betamethasone—Beclomethasone—psoriasis	0.000333	0.055	CbGdCrCtD
Suramin—SIRT1—Integrated Breast Cancer Pathway—NFKB1—psoriasis	0.000327	0.0031	CbGpPWpGaD
Suramin—PLA2G4A—Betamethasone—Fluocinolone Acetonide—psoriasis	0.000324	0.0534	CbGdCrCtD
Suramin—PLA2G4A—Dexamethasone—Fluocinolone Acetonide—psoriasis	0.000324	0.0534	CbGdCrCtD
Suramin—F2—Selenium Micronutrient Network—CRP—psoriasis	0.00032	0.00304	CbGpPWpGaD
Suramin—PLA2G2A—Spinal Cord Injury—CXCL8—psoriasis	0.00032	0.00303	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—NDUFA5—psoriasis	0.000307	0.00291	CbGpPWpGaD
Suramin—SIRT1—Integrated Breast Cancer Pathway—VEGFA—psoriasis	0.000297	0.00281	CbGpPWpGaD
Suramin—ARSA—Metabolism of proteins—ACE—psoriasis	0.000295	0.0028	CbGpPWpGaD
Suramin—F2—Selenium Micronutrient Network—ICAM1—psoriasis	0.000294	0.00279	CbGpPWpGaD
Suramin—PLA2G4A—Platelet homeostasis—NOS2—psoriasis	0.000294	0.00279	CbGpPWpGaD
Suramin—PLA2G4A—PDGF Pathway—STAT3—psoriasis	0.000294	0.00278	CbGpPWpGaD
Suramin—F2—Angiopoietin receptor Tie2-mediated signaling—NFKB1—psoriasis	0.000293	0.00278	CbGpPWpGaD
Suramin—PLA2G2A—MicroRNAs in cardiomyocyte hypertrophy—TNF—psoriasis	0.000292	0.00277	CbGpPWpGaD
Suramin—F2—Vitamin B12 Metabolism—NFKB1—psoriasis	0.000288	0.00273	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000286	0.00271	CbGpPWpGaD
Suramin—F2—Folate Metabolism—IFNG—psoriasis	0.000282	0.00267	CbGpPWpGaD
Suramin—SIRT1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	0.000281	0.00267	CbGpPWpGaD
Suramin—F2—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000279	0.00265	CbGpPWpGaD
Suramin—SIRT1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	0.000271	0.00257	CbGpPWpGaD
Suramin—SIRT1—Circadian rythm related genes—JUN—psoriasis	0.00027	0.00256	CbGpPWpGaD
Suramin—P2RY2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000264	0.0025	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—CYP2S1—psoriasis	0.000261	0.00247	CbGpPWpGaD
Suramin—FSHR—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000255	0.00242	CbGpPWpGaD
Suramin—SIRT1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	0.000246	0.00233	CbGpPWpGaD
Suramin—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—TP53—psoriasis	0.000244	0.00232	CbGpPWpGaD
Suramin—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—JUN—psoriasis	0.000237	0.00225	CbGpPWpGaD
Suramin—F2—Folate Metabolism—NFKB1—psoriasis	0.000235	0.00222	CbGpPWpGaD
Suramin—SIRT1—Cellular responses to stress—CXCL8—psoriasis	0.000234	0.00222	CbGpPWpGaD
Suramin—F2—GPCR downstream signaling—HCAR2—psoriasis	0.000231	0.0022	CbGpPWpGaD
Suramin—PLA2G4A—Endothelins—JUN—psoriasis	0.000231	0.00219	CbGpPWpGaD
Suramin—RYR1—Myometrial Relaxation and Contraction Pathways—IL6—psoriasis	0.00023	0.00218	CbGpPWpGaD
Suramin—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—NFKB1—psoriasis	0.000228	0.00217	CbGpPWpGaD
Suramin—SIRT1—Gene Expression—CARM1—psoriasis	0.000228	0.00216	CbGpPWpGaD
Suramin—F2—Angiopoietin receptor Tie2-mediated signaling—TNF—psoriasis	0.000228	0.00216	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—CCL20—psoriasis	0.000226	0.00214	CbGpPWpGaD
Suramin—F2—Vitamin B12 Metabolism—TNF—psoriasis	0.000224	0.00213	CbGpPWpGaD
Suramin—SIRT1—Integrated Breast Cancer Pathway—TP53—psoriasis	0.000224	0.00213	CbGpPWpGaD
Suramin—F2—Selenium Micronutrient Network—IFNG—psoriasis	0.000224	0.00212	CbGpPWpGaD
Suramin—PLA2G4A—AGE/RAGE pathway—JUN—psoriasis	0.000223	0.00211	CbGpPWpGaD
Suramin—PLA2G2A—Spinal Cord Injury—TNF—psoriasis	0.000222	0.00211	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—CCL20—psoriasis	0.000218	0.00207	CbGpPWpGaD
Suramin—SIRT1—Cellular responses to stress—JUN—psoriasis	0.000217	0.00206	CbGpPWpGaD
Suramin—PLA2G4A—AGE/RAGE pathway—NFKB1—psoriasis	0.000215	0.00203	CbGpPWpGaD
Suramin—F2—GPCR ligand binding—CCL20—psoriasis	0.000213	0.00202	CbGpPWpGaD
Suramin—ARSA—Metabolism of lipids and lipoproteins—APOE—psoriasis	0.000212	0.00201	CbGpPWpGaD
Suramin—SIRT1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	0.000211	0.002	CbGpPWpGaD
Suramin—F2—Signaling by GPCR—HCAR2—psoriasis	0.00021	0.00199	CbGpPWpGaD
Suramin—SIRT1—Cellular responses to stress—NFKB1—psoriasis	0.000209	0.00198	CbGpPWpGaD
Suramin—P2RY2—GPCR ligand binding—CXCL8—psoriasis	0.000201	0.00191	CbGpPWpGaD
Suramin—P2RY2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	0.0002	0.0019	CbGpPWpGaD
Suramin—ARSA—Metabolism—CARM1—psoriasis	0.000198	0.00187	CbGpPWpGaD
Suramin—PLA2G2A—Spinal Cord Injury—TP53—psoriasis	0.000196	0.00186	CbGpPWpGaD
Suramin—FSHR—GPCR ligand binding—CXCL8—psoriasis	0.000194	0.00184	CbGpPWpGaD
Suramin—PLA2G4A—AGE/RAGE pathway—STAT3—psoriasis	0.000193	0.00183	CbGpPWpGaD
Suramin—PLA2G4A—Signaling by GPCR—HCAR2—psoriasis	0.000192	0.00182	CbGpPWpGaD
Suramin—SIRT1—Cellular responses to stress—VEGFA—psoriasis	0.00019	0.0018	CbGpPWpGaD
Suramin—SIRT1—Cellular responses to stress—STAT3—psoriasis	0.000188	0.00178	CbGpPWpGaD
Suramin—F2—Selenium Micronutrient Network—NFKB1—psoriasis	0.000186	0.00177	CbGpPWpGaD
Suramin—SIRT1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	0.000186	0.00176	CbGpPWpGaD
Suramin—ARSA—Metabolism of lipids and lipoproteins—PPARG—psoriasis	0.000185	0.00175	CbGpPWpGaD
Suramin—ARSA—Metabolism of proteins—LEP—psoriasis	0.000183	0.00174	CbGpPWpGaD
Suramin—F2—Folate Metabolism—TNF—psoriasis	0.000182	0.00173	CbGpPWpGaD
Suramin—F2—Vitamin B12 Metabolism—IL6—psoriasis	0.000181	0.00172	CbGpPWpGaD
Suramin—PLA2G2A—Spinal Cord Injury—IL6—psoriasis	0.00018	0.0017	CbGpPWpGaD
Suramin—SIRT1—Circadian rythm related genes—TP53—psoriasis	0.000178	0.00169	CbGpPWpGaD
Suramin—F2—Hemostasis—ITGAL—psoriasis	0.000176	0.00167	CbGpPWpGaD
Suramin—PLA2G4A—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	0.000171	0.00162	CbGpPWpGaD
Suramin—PLA2G4A—Dexamethasone—Hydrocortisone—psoriasis	0.000164	0.027	CbGdCrCtD
Suramin—PLA2G4A—Betamethasone—Hydrocortisone—psoriasis	0.000164	0.027	CbGdCrCtD
Suramin—SIRT1—Circadian rythm related genes—IL6—psoriasis	0.000163	0.00155	CbGpPWpGaD
Suramin—F2—Folate Metabolism—TP53—psoriasis	0.000161	0.00153	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—ITGAL—psoriasis	0.000161	0.00152	CbGpPWpGaD
Suramin—F2—Metabolism of proteins—REN—psoriasis	0.000157	0.00149	CbGpPWpGaD
Suramin—PLA2G4A—Betamethasone—Dexamethasone—psoriasis	0.000152	0.025	CbGdCrCtD
Suramin—PLA2G4A—Dexamethasone—Betamethasone—psoriasis	0.000152	0.025	CbGdCrCtD
Suramin—PLA2G4A—Betamethasone—Triamcinolone—psoriasis	0.000148	0.0245	CbGdCrCtD
Suramin—PLA2G4A—Dexamethasone—Triamcinolone—psoriasis	0.000148	0.0245	CbGdCrCtD
Suramin—F2—Folate Metabolism—IL6—psoriasis	0.000147	0.0014	CbGpPWpGaD
Suramin—F2—Selenium Micronutrient Network—TNF—psoriasis	0.000145	0.00137	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—NDUFA5—psoriasis	0.000144	0.00137	CbGpPWpGaD
Suramin—PLA2G4A—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	0.000144	0.00136	CbGpPWpGaD
Suramin—SIRT1—Cellular responses to stress—TP53—psoriasis	0.000143	0.00136	CbGpPWpGaD
Suramin—PLA2G4A—Betamethasone—Prednisone—psoriasis	0.000141	0.0232	CbGdCrCtD
Suramin—PLA2G4A—Dexamethasone—Prednisone—psoriasis	0.000141	0.0232	CbGdCrCtD
Suramin—PLA2G4A—Dexamethasone—Prednisolone—psoriasis	0.000137	0.0227	CbGdCrCtD
Suramin—PLA2G4A—Betamethasone—Prednisolone—psoriasis	0.000137	0.0227	CbGdCrCtD
Suramin—PLA2G2A—Metabolism of lipids and lipoproteins—APOE—psoriasis	0.000137	0.0013	CbGpPWpGaD
Suramin—SIRT1—Gene Expression—VDR—psoriasis	0.000136	0.00129	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000135	0.00128	CbGpPWpGaD
Suramin—PLA2G4A—PDGFR-beta signaling pathway—JUN—psoriasis	0.000134	0.00127	CbGpPWpGaD
Suramin—SIRT1—Cellular responses to stress—IL6—psoriasis	0.000131	0.00124	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—CARM1—psoriasis	0.000127	0.00121	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—SOCS1—psoriasis	0.000124	0.00118	CbGpPWpGaD
Suramin—F2—Signaling Pathways—HCAR2—psoriasis	0.000124	0.00118	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—CYP2S1—psoriasis	0.000123	0.00116	CbGpPWpGaD
Suramin—ARSA—Metabolism of proteins—CXCL8—psoriasis	0.000122	0.00115	CbGpPWpGaD
Suramin—ARSA—Metabolism—CAT—psoriasis	0.000122	0.00115	CbGpPWpGaD
Suramin—F2—GPCR downstream signaling—CCL20—psoriasis	0.00012	0.00114	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—SOCS1—psoriasis	0.00012	0.00114	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism of lipids and lipoproteins—PPARG—psoriasis	0.000119	0.00113	CbGpPWpGaD
Suramin—P2RY2—Signaling by GPCR—TYK2—psoriasis	0.000119	0.00112	CbGpPWpGaD
Suramin—F2—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	0.000117	0.00111	CbGpPWpGaD
Suramin—F2—Selenium Micronutrient Network—IL6—psoriasis	0.000117	0.00111	CbGpPWpGaD
Suramin—PLA2G4A—PDGFR-beta signaling pathway—STAT3—psoriasis	0.000116	0.0011	CbGpPWpGaD
Suramin—FSHR—Signaling by GPCR—TYK2—psoriasis	0.000114	0.00109	CbGpPWpGaD
Suramin—P2RY2—GPCR downstream signaling—CXCL8—psoriasis	0.000114	0.00108	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—HCAR2—psoriasis	0.000114	0.00108	CbGpPWpGaD
Suramin—F2—Peptide ligand-binding receptors—CXCL8—psoriasis	0.000112	0.00107	CbGpPWpGaD
Suramin—FSHR—GPCR downstream signaling—CXCL8—psoriasis	0.00011	0.00104	CbGpPWpGaD
Suramin—F2—Signaling by GPCR—CCL20—psoriasis	0.000109	0.00104	CbGpPWpGaD
Suramin—F2—Signaling Pathways—TAGAP—psoriasis	0.000108	0.00102	CbGpPWpGaD
Suramin—P2RY2—Signaling by GPCR—CXCL8—psoriasis	0.000103	0.000979	CbGpPWpGaD
Suramin—PLA2G4A—Signaling by GPCR—CCL20—psoriasis	9.99e-05	0.000947	CbGpPWpGaD
Suramin—FSHR—Signaling by GPCR—CXCL8—psoriasis	9.97e-05	0.000945	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—TAGAP—psoriasis	9.85e-05	0.000934	CbGpPWpGaD
Suramin—F2—Metabolism of proteins—ACE—psoriasis	9.79e-05	0.000929	CbGpPWpGaD
Suramin—PLA2G4A—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	9.52e-05	0.000903	CbGpPWpGaD
Suramin—SIRT1—Gene Expression—PPARG—psoriasis	9.49e-05	0.0009	CbGpPWpGaD
Suramin—ARSA—Metabolism—APOE—psoriasis	9.44e-05	0.000895	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—APOE—psoriasis	9.17e-05	0.00087	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—LEP—psoriasis	9.17e-05	0.00087	CbGpPWpGaD
Suramin—PLA2G4A—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	9.17e-05	0.000869	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—APOE—psoriasis	8.86e-05	0.00084	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—LEP—psoriasis	8.86e-05	0.00084	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—NFKBIA—psoriasis	8.55e-05	0.000811	CbGpPWpGaD
Suramin—PLA2G4A—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	8.32e-05	0.000789	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—NFKBIA—psoriasis	8.25e-05	0.000783	CbGpPWpGaD
Suramin—ARSA—Metabolism—PPARG—psoriasis	8.22e-05	0.00078	CbGpPWpGaD
Suramin—F2—Platelet activation, signaling and aggregation—VEGFA—psoriasis	8.1e-05	0.000768	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—CAT—psoriasis	7.83e-05	0.000743	CbGpPWpGaD
Suramin—F2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	7.54e-05	0.000716	CbGpPWpGaD
Suramin—PLA2G4A—Platelet activation, signaling and aggregation—VEGFA—psoriasis	7.4e-05	0.000702	CbGpPWpGaD
Suramin—F2—Hemostasis—NOS2—psoriasis	7.2e-05	0.000683	CbGpPWpGaD
Suramin—PLA2G4A—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	7.13e-05	0.000676	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—TYK2—psoriasis	7e-05	0.000664	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—TYK2—psoriasis	6.76e-05	0.000641	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—NOS2—psoriasis	6.59e-05	0.000625	CbGpPWpGaD
Suramin—F2—Signaling Pathways—CCL20—psoriasis	6.45e-05	0.000612	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.44e-05	0.00061	CbGpPWpGaD
Suramin—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	6.29e-05	0.000596	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—CXCL8—psoriasis	6.1e-05	0.000578	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—APOE—psoriasis	6.08e-05	0.000577	CbGpPWpGaD
Suramin—F2—Metabolism of proteins—LEP—psoriasis	6.08e-05	0.000577	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—CARM1—psoriasis	6e-05	0.000569	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—CCL20—psoriasis	5.9e-05	0.000559	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—CXCL8—psoriasis	5.89e-05	0.000558	CbGpPWpGaD
Suramin—P2RY2—Signaling by GPCR—IL6—psoriasis	5.8e-05	0.00055	CbGpPWpGaD
Suramin—F2—GPCR ligand binding—CXCL8—psoriasis	5.75e-05	0.000545	CbGpPWpGaD
Suramin—F2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	5.72e-05	0.000543	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—JUN—psoriasis	5.67e-05	0.000537	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.61e-05	0.000532	CbGpPWpGaD
Suramin—FSHR—Signaling by GPCR—IL6—psoriasis	5.6e-05	0.000531	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—JUN—psoriasis	5.47e-05	0.000519	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—NFKB1—psoriasis	5.45e-05	0.000517	CbGpPWpGaD
Suramin—PLA2G2A—Metabolism—PPARG—psoriasis	5.3e-05	0.000503	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—NFKB1—psoriasis	5.27e-05	0.0005	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—VEGFA—psoriasis	4.95e-05	0.000469	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—STAT3—psoriasis	4.9e-05	0.000465	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—VEGFA—psoriasis	4.78e-05	0.000453	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—STAT3—psoriasis	4.73e-05	0.000449	CbGpPWpGaD
Suramin—F2—Hemostasis—VEGFA—psoriasis	4.17e-05	0.000396	CbGpPWpGaD
Suramin—F2—Metabolism of proteins—CXCL8—psoriasis	4.04e-05	0.000383	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—VEGFA—psoriasis	3.82e-05	0.000362	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—TP53—psoriasis	3.74e-05	0.000355	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—CAT—psoriasis	3.69e-05	0.00035	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—TP53—psoriasis	3.61e-05	0.000343	CbGpPWpGaD
Suramin—F2—Signaling Pathways—SOCS1—psoriasis	3.55e-05	0.000337	CbGpPWpGaD
Suramin—P2RY2—Signaling Pathways—IL6—psoriasis	3.42e-05	0.000325	CbGpPWpGaD
Suramin—F2—Signaling by GPCR—TYK2—psoriasis	3.39e-05	0.000321	CbGpPWpGaD
Suramin—FSHR—Signaling Pathways—IL6—psoriasis	3.31e-05	0.000314	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—SOCS1—psoriasis	3.25e-05	0.000308	CbGpPWpGaD
Suramin—F2—GPCR downstream signaling—CXCL8—psoriasis	3.25e-05	0.000308	CbGpPWpGaD
Suramin—F2—Hemostasis—TP53—psoriasis	3.15e-05	0.000299	CbGpPWpGaD
Suramin—PLA2G4A—Signaling by GPCR—TYK2—psoriasis	3.1e-05	0.000294	CbGpPWpGaD
Suramin—F2—Signaling by GPCR—CXCL8—psoriasis	2.95e-05	0.00028	CbGpPWpGaD
Suramin—PLA2G4A—Hemostasis—TP53—psoriasis	2.88e-05	0.000273	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—APOE—psoriasis	2.87e-05	0.000272	CbGpPWpGaD
Suramin—PLA2G4A—Signaling by GPCR—CXCL8—psoriasis	2.7e-05	0.000256	CbGpPWpGaD
Suramin—F2—Signaling Pathways—LEP—psoriasis	2.62e-05	0.000249	CbGpPWpGaD
Suramin—F2—Signaling Pathways—APOE—psoriasis	2.62e-05	0.000249	CbGpPWpGaD
Suramin—PLA2G4A—Metabolism—PPARG—psoriasis	2.5e-05	0.000237	CbGpPWpGaD
Suramin—F2—Signaling Pathways—NFKBIA—psoriasis	2.44e-05	0.000232	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—LEP—psoriasis	2.4e-05	0.000227	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—APOE—psoriasis	2.4e-05	0.000227	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—NFKBIA—psoriasis	2.23e-05	0.000212	CbGpPWpGaD
Suramin—F2—Signaling Pathways—TYK2—psoriasis	2e-05	0.00019	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—TYK2—psoriasis	1.83e-05	0.000174	CbGpPWpGaD
Suramin—F2—Signaling Pathways—CXCL8—psoriasis	1.74e-05	0.000165	CbGpPWpGaD
Suramin—F2—Signaling by GPCR—IL6—psoriasis	1.66e-05	0.000157	CbGpPWpGaD
Suramin—F2—Signaling Pathways—JUN—psoriasis	1.62e-05	0.000154	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—CXCL8—psoriasis	1.59e-05	0.000151	CbGpPWpGaD
Suramin—F2—Signaling Pathways—NFKB1—psoriasis	1.56e-05	0.000148	CbGpPWpGaD
Suramin—PLA2G4A—Signaling by GPCR—IL6—psoriasis	1.51e-05	0.000144	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—JUN—psoriasis	1.48e-05	0.00014	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—NFKB1—psoriasis	1.43e-05	0.000135	CbGpPWpGaD
Suramin—F2—Signaling Pathways—VEGFA—psoriasis	1.41e-05	0.000134	CbGpPWpGaD
Suramin—F2—Signaling Pathways—STAT3—psoriasis	1.4e-05	0.000133	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—VEGFA—psoriasis	1.29e-05	0.000123	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—STAT3—psoriasis	1.28e-05	0.000121	CbGpPWpGaD
Suramin—F2—Signaling Pathways—TP53—psoriasis	1.07e-05	0.000101	CbGpPWpGaD
Suramin—F2—Signaling Pathways—IL6—psoriasis	9.78e-06	9.28e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—TP53—psoriasis	9.78e-06	9.27e-05	CbGpPWpGaD
Suramin—PLA2G4A—Signaling Pathways—IL6—psoriasis	8.95e-06	8.49e-05	CbGpPWpGaD
